BR Biopharma (NASDAQ:BRBI) Trading Up 1.1% - Time to Buy?

Key Points

• Shares of BR Biopharma (NASDAQ:BRBI) rose about 1.1% to $15.26 intraday, trading as high as $15.73 on light volume (2,443 shares, ~41% below average) and sitting above its 50‑day moving average of $14.89.
• Analyst sentiment is negative: Weiss Ratings initiated coverage with a "sell (e-)" and the stock carries a consensus rating of Sell.
• The company reported quarterly results of $0.16 EPS on $23.81 million revenue, and hedge fund Acuitas Investments disclosed a new 3,000‑share (~$45,000) stake representing about 3.2% of its portfolio.

Shares of BR Biopharma, Inc. (NASDAQ:BRBI - Get Free Report) shot up 1.1% during trading on Wednesday . The company traded as high as $15.73 and last traded at $15.26. 2,443 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 4,107 shares. The stock had previously closed at $15.10.

Analyst Ratings Changes

Separately, Weiss Ratings began coverage on shares of BR Biopharma in a research note on Friday, February 13th. They issued a "sell (e-)" rating on the stock. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of "Sell".

BR Biopharma Price Performance

The business has a 50 day moving average price of $14.89.

BR Biopharma (NASDAQ:BRBI - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $0.16 earnings per share for the quarter. The firm had revenue of $23.81 million for the quarter.

Institutional Investors Weigh In On BR Biopharma

A hedge fund recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC bought a new stake in shares of BR Biopharma, Inc. (NASDAQ:BRBI - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,000 shares of the company's stock, valued at approximately $45,000. BR Biopharma comprises about 3.2% of Acuitas Investments LLC's investment portfolio, making the stock its 7th largest holding.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.